A previous study in children 1–4 years of age in a high transmission area of Papua New Guinea demonstrated that IgG, IgG1 and/or IgG3 antibodies against MSP-2, AMA-1, EBA-175, EBA-140, and EBA-181 were associated with a higher risk of clinical malaria [54], which was thought to be due to not achieving a threshold level required for protection from clinical malaria. This evidence concerns the gene IGHG3 and malaria.